AEGERION PHARMACEUTICALS, INC.

CAMBRIDGE, MA How do I update this listing?

Aegerion Pharmaceuticals is based out of Cambridge. Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-altering therapeutics for rare and often fatal genetic lipid disorders. Its lead product in Phase III clinical development, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. Lomitapide has demonstrated the lowering of both bad cholesterol (LDL-C) and triglyceride (TG) levels in patients with a rare form of hypercholesterolemia. The company plans to initiate a clinical program to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).Whalewisdom has at least 1 13D filings, and 204 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2010-06-28. The notice included securities offered of Other

Create Alert

Contact Info

aegerion pharmaceuticals, inc.
ONE MAIN STREET
CAMBRIDGE MA    02142

Business Phone: (617) 500-7867
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS
Current 13D/G Holdings
Stock Sector Shares Held Market Value Rank Source Source Date
Novelion Therapeutics Inc (NVLN) HEALTH CARE 2,621,840 3,224,863.69 1 13D 2016-06-14

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2010-06-28 D/A PHARMACEUTICALS Other 19,814,760 18,314,760 1,500,000
2010-02-09 D/A PHARMACEUTICALS Other 16,814,760 16,814,760 0
2009-07-15 D/A PHARMACEUTICALS Other 15,814,760 13,562,101 2,252,659
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ALISON DE BORD subscription required
    DIRECTOR
ALISON KILEY subscription required
    DIRECTOR
ANTONIO M. GOTTO subscription required
    DIRECTOR
CHRISTINE PELLIZZARI subscription required
    EXECUTIVE OFFICER
DAVID ARKOWITZ subscription required
    DIRECTOR
DAVID SCHEER subscription required
    DIRECTOR
JASON FISHERMAN subscription required
    DIRECTOR
MICHELE OLLIER subscription required
    DIRECTOR
PETER GARRAMBONE subscription required
    DIRECTOR
WILLIAM H. LEWIS subscription required
    EXECUTIVE OFFICER
WILLIAM SASIELA subscription required
    EXECUTIVE OFFICER

Elevate your investments